To examine the effect of a strong cytochrome P450 (CYP) 3A inhibitor, ketoconazole, on the pharmacokinetics, safety and tolerability of venetoclax.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Venetoclax has demonstrated clinical efficacy and safety in a variety of haematological malignancies.
• In vitro, venetoclax and its major metabolite (M27) are metabolized primarily by CYP3A.
WHAT THIS STUDY ADDS
• Ketoconazole increased venetoclax mean C max and AUC ∞ by 2.3-and 6.4-fold, respectively, compared to administration of venetoclax alone. These results indicate that CYP3A plays a major role in elimination of venetoclax in patients.
• These results suggest the need to avoid concomitant use of venetoclax with strong and moderate CYP3A inhibitors in CLL patients during the venetoclax ramp-up phase.
Tables of Links

TARGETS
Other protein targets [2] BCL-2 Family
BCL-XL BCL-2
Transporters [3] Introduction Venetoclax (ABT-199, GDC-0199) is a selective, potent, firstin-class, BCL-2 family protein inhibitor in the biarylacylsulfonamide chemical class that restores programmed cell death (apoptosis) in cancer cells. Antiapoptotic BCL-2 family members are associated with tumour initiation, disease progression and chemotherapy resistance. Overexpression of BCL-2 family members is a major contributor to the pathogenesis of lymphoid malignancies. Antagonism of the action of these proteins may enhance response to therapy and overcome chemoresistance, and thus, these proteins of the apoptotic pathway are compelling targets for anticancer therapy [5] . Venetoclax has been studied in multiple clinical trials and has demonstrated efficacy in patients with haematological malignancies as both a single agent and combination therapy [6] [7] [8] [9] [10] [11] . The pharmacokinetics of venetoclax has been characterized in several studies [6, [12] [13] [14] [15] . Venetoclax plasma concentration peaked around 6 to 8 h after a single dose and the terminal phase elimination half-life (t 1/2 ) was approximately 19 h in subjects with chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL). At steady state, venetoclax area under the plasma concentration-time curve (AUC) increased proportionally over the dose range of 150-800 mg day À1 [6] . Food increased venetoclax exposure by 3-5 fold [13, 14] . Following a single oral dose of 200 mg (100 μCi) of [ 14 C]venetoclax to four healthy volunteers, recovery of total radioactive dose was 100% (AE 5%), with faeces being the major route of elimination of the administered dose, whereas urinary excretion was minimal (<0.1%) [15] . The chemical structure of venetoclax and M27 has been reported previously [15, 16] . Nonclinical studies indicated that venetoclax and its major metabolite (M27), formed by oxidation, are metabolized primarily by CYP3A [15] . Ketoconazole is the prototypical azole class antifungal agent. Ketoconazole was selected in this study because it is a potent inhibitor of CYP3A4 and was recommended by the Food and Drug Administration as a probe drug for investigating the effect of inhibition on the pharmacokinetics of CYP3A substrates [17] . Coadministration of ketoconazole may result in increased plasma concentrations of drugs primarily metabolized by cytochrome P450 (CYP) 3A4, which in turn could increase or prolong their therapeutic and adverse effects. Additionally, other frequently used azole antifungal agents, such as posaconazole and fluconazole, used to treat fungal infections in patients with cancer, have been shown to inhibit CYP3A enzymes. In vitro, venetoclax is also shown to be a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), which are inhibited by ketoconazole [18] . Therefore, the current study was conducted to assess the effect of ketoconazole on the pharmacokinetics of venetoclax and guide dosing recommendations in patients requiring concomitant use of CYP3A inhibitors with venetoclax.
Methods
Patients
Adult men and women 18 years of age and older with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) with an Eastern Cooperative Oncology Group (ECOG) performance score between 0 and 2 were eligible to enrol in the study. Figure 1 ). All tablets were swallowed in the morning with 240 ml of water, within 30 minutes after completion of a standardized low-fat breakfast.
Blood sample collection and bioanalytical methods
Blood samples for venetoclax and M27 assay were collected in 3 ml K 2 EDTA-containing plastic tubes by venipuncture prior to dosing (0 h) and at 2, 4, 6, 8, 10, 12, 24, 48, 72 and 96 h after dosing on Day 1 and Day 8. Plasma concentrations of venetoclax and M27 metabolite were determined using liquid chromatography with tandem mass spectrometric detection [19] . The lower limits of quantitation for the venetoclax and M27 assays were 2.05 and 2.04 ng ml À1 , respectively. The precision values for the quality control samples of venetoclax and M27 were ≤12.2% and ≤11.6%, respectively.
Pharmacokinetic analysis
The pharmacokinetic parameters of venetoclax and M27 metabolite on Day 1 and Day 8 were estimated using noncompartmental methods in SAS v9.2. Pharmacokinetic parameters estimated included: the maximum observed concentration (C max ), the time to maximum concentration (T max ), the apparent terminal phase elimination rate constant (β), the terminal phase elimination half-life (t 1/2 ), the AUC from time 0 to time of the last measurable concentration (AUC t ) and extrapolated to infinite time (AUC ∞ ).
Safety and tolerability assessments
Treatment-emergent adverse events were defined as adverse events with onset after the first dose of venetoclax through the end of the study. The number and percentage of subjects having treatment-emergent adverse events were summarized with a breakdown by the following three regimens: before ketoconazole administration (venetoclax alone, Days 1-4), ketoconazole alone (Days 5-7), and venetoclax and ketoconazole coadministration (Day 8 to the end of the study). Adverse event severity was classified according to National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Figure 1 Study design Events (CTCAE) Version 4.0 toxicity grade. Serious adverse events and events leading to discontinuation of treatment were summarized. Laboratory test results and vital sign values were evaluated for possible clinical significance using predefined criteria.
Statistical analysis
To assess the effect of ketoconazole on venetoclax and M27 pharmacokinetics, an analysis of variance (ANOVA) was performed for T max , β and the natural logarithms of C max , AUC t and AUC ∞ using PROC GLM in SAS v9. The power calculations assumed the error term variance of 0.1724 for the natural logarithm of dose-normalized C max . Complete data from 10 subjects would provide at least 80% power to detect an 80% increase (or 45% decrease) in the central value of C max between the two regimens (venetoclax alone vs. venetoclax in combination with ketoconazole).
Results
Patients and baseline demographic characteristics
Twelve patients were enrolled in the study and all of them completed the study. Their mean (standard deviation [SD]) weight was 83.3 (18.5) kg and the median age was 71.5 years (range: 37-82) ( Table 1) . One patient was excluded from the statistical analysis of pharmacokinetic parameters because the protocol-specified dose of 400 mg ketoconazole was not taken on Day 6-Day 8; the subject took 200 mg ketoconazole on these days. Following dosing on Day 8, two pharmacokinetic samples in the terminal elimination phase (48 and 96 h) were not collected for one subject. AUC ∞ and t 1/2 were not calculated for this subject on Day 8, as valid estimates of β could not be determined.
Effect of ketoconazole on venetoclax and M27 pharmacokinetics
The mean (+ SD) plasma concentration-time profiles for venetoclax and M27, following administration of 50 mg venetoclax alone on Study Day 1 and coadministration with ketoconazole on Study Day 8, are presented in Figure 2 .
Pharmacokinetic parameters of venetoclax and M27, with and without ketoconazole, are presented in Table 2 . After a 50 mg oral dose, the median time to reach peak plasma concentrations of venetoclax was 8 h on Study Day 1 with a mean t 1/2 of 19.1 h.
When venetoclax was coadministered with ketoconazole, the venetoclax median T max did not change but the venetoclax C max , AUC t , AUC ∞ and t 1/2 significantly increased (P < 0.05). Ketoconazole increased venetoclax C max and AUC ∞ in all subjects ( Figure 3 ) with a mean increase of 2.3-and 6.4-fold, respectively, compared to administration of venetoclax alone (Table 3) . While the mean increase in AUC was 6.4-fold, the variability was high (range: 2-to 12-fold increase). Two subjects reported receiving acid-suppressing agents during the study. No change in point estimates for venetoclax C max and AUC ∞ were noted in the analysis conducted excluding data from these two subjects. One subject reported taking a protocol exclusionary medication, diltiazem, a moderate CYP3A inhibitor, before and throughout the study. Analyses conducted excluding this subject showed no change in point estimate for venetoclax C max (2.3-fold) and a slight increase in AUC ∞ (7.2-fold vs. 6.4-fold) following coadministration with ketoconazole. Interestingly, the one subject who was excluded from statistical analysis for taking an incorrect ketoconazole dose of 200 mg on Days 6-8 showed a 2.3-fold increase in C max and 3.5-fold increase in AUC, suggesting the interaction was perhaps not maximal at 200 mg ketoconazole daily. Given the large variability in AUC increases observed in this study, this may have merely been due to interpatient variability. In contrast to venetoclax, M27 metabolite T max was delayed and both C max and AUC t decreased in most subjects with a mean decrease in C max and AUC t by approximately 50% and 30%, respectively, after coadministration of venetoclax with ketoconazole (Table 3 ).
Safety and tolerability
Five patients (41.7%) reported adverse events when treated with venetoclax alone, two (16.7%) patients reported adverse events when treated with ketoconazole alone, and eight (66.7%) patients reported adverse events when treated with Table 2 Mean AE SD (range) pharmacokinetic parameters of venetoclax and M27 metabolite the combination of venetoclax and ketoconazole. The majority of adverse events reported were mild or moderate in severity (grade 1 or grade 2). One subject experienced a grade 3 adverse event of hypokalemia on the day of treatment with venetoclax alone. This adverse event ended after 2 days and was not considered by the investigator or sponsor to be related to venetoclax treatment. Grade 3 events of thrombocytopenia and ureteric obstruction were reported when venetoclax was coadministered with ketoconazole. Thrombocytopenia was considered by the investigator as possibly related to both venetoclax and ketoconazole treatment and was ongoing at the end of the study; the ureteric obstruction (the only serious adverse event reported in this study), which occurred on Day 11, was considered by the investigator to be unrelated to either study drug. No deaths were reported and there were no interruptions, reductions or discontinuations of venetoclax or ketoconazole due to adverse events. Four adverse events in clinical laboratory investigations were reported (grade 2 hyperphosphatemia, grade 1 serum creatinine increase, grade 2 hyperkalemia, grade 2 hypocalcemia); all were nonserious and resolved with no action taken with regard to study drug administration. No clinically meaningful abnormalities in vital signs, electrocardiogram parameters or other laboratory values were observed.
Discussion
This is the first clinical pharmacokinetic study to determine the potential effect of any CYP3A inhibitor on the Figure 3 Individual venetoclax C max and AUC ∞ values after administration of 50 mg venetoclax alone on Day 1 and after coadministration with 400 mg ketoconazole on Day 8 (n = 11). *Red line denotes the subject who experienced thrombocytopenia and also took diltiazem, a moderate CYP3A inhibitor, throughout the study Table 3 Point estimates and 90% confidence intervals of venetoclax and M27 metabolite pharmacokinetic parameters pharmacokinetics of venetoclax in patients with haematological malignancies. In this study, treatment with oral ketoconazole increased venetoclax mean C max and AUC ∞ by 2.3-and 6.4-fold, respectively, compared to venetoclax alone. An increase in venetoclax AUC ∞ of 6.4-fold combined with a >2-fold increase in its t 1/2 strongly suggests the key role of CYP3A4 in venetoclax elimination in patients. Inhibition of P-gp and BCRP may have also contributed to the increase in venetoclax exposures via an increase in absorption as ketoconazole has inhibitory effects on P-gp and BCRP [18] . It must be noted that while a dose of 50 mg was used in this study, higher doses (e.g., 400 mg) are used therapeutically and the magnitude of the interaction at higher doses might be different. Although the range of body weight of patients enrolled in the study was wide (50.8-119 kg), it must be noted that no relationship between body weight and AUC ∞ was observed ( Figure 4) . Additionally, the majority of the subjects were males and white. In an earlier study, the covariates weight, sex and race did not affect venetoclax clearance [14] . Ketoconazole effects on venetoclax pharmacokinetics were less profound in magnitude when compared to the effects observed on midazolam, a sensitive and often used CYP3A probe substrate. Stoch et al. reported an increase of 5.4-and 14.0-fold in C max and AUC ∞ of midazolam in a healthy volunteer study in which 400 mg ketoconazole once daily was administered for 5 days and a 2 mg midazolam dose was coadministered with ketoconazole on Day 5 [20] .
Plasma concentrations of ketoconazole were not measured to confirm compliance with ketoconazole therapy. An AUC increase of >5-fold in the presence of ketoconazole indicates that venetoclax is a sensitive CYP3A substrate. The exposure-efficacy analyses using data from CLL subjects indicated that the rate of objective response is similar, with 0.5-to 2.0-fold change in exposure from that typically achieved at the 400 mg QD dosage regimen [21] , but a concentration dependent effect of venetoclax on progression free survival was observed [22] . At a venetoclax dose of 1200 mg QD, where venetoclax exposures are approximately 2.5-fold higher than those achieved at 400 mg QD, the maximum tolerated dose of venetoclax was not reached [23] [24] [25] . On the other hand, venetoclax therapy in CLL patients starts according to a weekly ramp-up dosing schedule from 20 mg to the recommended dose of 400 mg over a period of 5 weeks to minimize the risk for tumour lysis syndrome. Therefore, based on the results from this study and the exposure-efficacy and safety venetoclax profile, coadministration of venetoclax with moderate and strong inhibitors or inducers of CYP3A should be avoided during the ramp-up phase in CLL patients. For patients who have completed the ramp-up phase, a modification of venetoclax dose for use with strong and moderate inhibitors or inducers of CYP3A is recommended [26] .
M27 mean C max and AUC t decreased by approximately 50% and 30%, respectively, after coadministration of venetoclax with ketoconazole. A decrease in C max of M27 can be explained by its decreased rate of formation from venetoclax mediated by CYP3A inhibition. However, a decrease in AUC t was not expected given that M27 is also a CYP3A substrate and its metabolic clearance was reduced in the presence of ketoconazole. The decrease in AUC t is an artefact of the shorter pharmacokinetic sampling duration. M27 T max was significantly delayed (median = 48 h), only two PK samples were collected beyond C max (at 72 and 96 h) and the half-life of M27 was significantly prolonged in the presence of ketoconazole. Taken together, this resulted in inability to accurately calculate M27 AUC ∞ and t 1/2 on Day 8 for eight subjects, as valid estimates of β could not be determined due to the lack of three concentration-time data points after T max . In four subjects where AUC ∞ estimates could be calculated, the percentage extrapolated AUC was very high (>50%), further emphasizing the limitation of a shorter PK sampling duration. It is worth noting that the M27 metabolite was not identified at the time of study design and conduct and hence the PK sampling scheme was based solely on the expected effect on venetoclax pharmacokinetics. If M27 concentrations were measured long enough, both M27 AUC t and AUC ∞ estimates would have been higher as can be inferred from Figure 2 showing relatively flat M27 concentrations in the presence of ketoconazole beyond 24 h. Overall, the results observed are consistent with those expected from CYP3A inhibition of venetoclax and M27 metabolism and M27 formation from venetoclax.
The pharmacokinetics of navitoclax, a dual inhibitor of BCL-2 and BCL-X L , were not significantly affected by ketococonazole [27] suggesting that, unlike venetoclax, CYP3A does not play a major role in the elimination of navitoclax. Thrombocytopenia caused by BCL-X L inhibition has been the primary dose-limiting toxicity in the clinical development of navitoclax. Venetoclax. a selective BCL-2 inhibitor, has an improved safety profile than dual BCL-2/ BCL-X L inhibitors by avoiding dose-limiting thrombocytopenia. In this study, grade 3 thrombocytopenia was reported in only one subject (8.3%), a frequency similar to that reported previously in a Phase 1 venetoclax monotherapy study in R/R NHL patients [23] . Venetoclax exposures in this subject were within the range of exposures observed in other subjects who did not develop thrombocytopenia. Overall, coadministration of venetoclax with and without ketoconazole was well tolerated in this Phase 1 study in 12 patients with R/R NHL with no other serious (grades 3, 4 or 5) adverse events attributed to study drugs.
Figure 4
Relationship between body weight and venetoclax AUC ∞ on Day 1
